Sunwin ( SUWN ) explodiert !

Sunwin International Neutraceuticals Issues Corporate Update and Business Outlook for Fiscal Year of 2008



QUFU, CHINA, -- (MARKET WIRE) -- 08/20/07 -- Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world's leading producers and distributors of all-natural, zero-calorie Stevia in China, today announced management's recap of fiscal 2007 and its business outlook for fiscal year ended April 30, 2008.

In the fiscal year 2007, we made significant capital investments for the future of our company and achieved several major milestones as follows:


--  Completed $4.2 million private equity offering.
--  Completed construction of new stevia manufacturing facilities.  The
   new facilities will yield 1 ton of premium stevia (A360) per day or an
   estimated 300 tons per year.
--  Launched and branded our OnlySweet product lines in the U.S. markets.
   OnlySweet products are currently available over 3,000 grocery stores in the
   U.S.
--  Developed 5 new Chinese herb-based products.  We anticipate these
   products will receive approval from the government for sale in China this
   fiscal year.
--  Developed new veterinary feeds that are based on residue from stevia
   production.  The new veterinary feeds will be ready for marketing in the
   2008 fiscal year.

-- Veterinärmedizin und Zufuhren: Wir erwarten unsere Medizin und Zufuhren zu
   Wachstum von ungefähr 30% bis ungefähr $4.2 Million in den Einkommen erfahren
   mit 9% dem Reingewinn steuerlichem 2008. Wir erwarten zur stevia-gegründeten Produkteinführung
   Tierarzt zieht innen den kommenden Monat und das Abhängen nach TIMING der Produkteinführung ein
   und Annahme der Einkommen Beitrag konnte eine Durchlaufrate von $12 erreichen
   Million Ende dieses steuerlichen Jahres mit erheblich stark grobem
   Seitenränder.

-- Chinesische Kraut-Medizin: Wir nehmen bedeutendes Wachstum diesbezüglich vorweg
   Abteilung abhängig von dem TIMING von Zustimmungen in China. Wachstum von diesem
   Abteilung könnte wie 50% so hoch sein, das ungefähr $5.4 erbringen könnte
   Million in den Einkommen mit 10% Nettogewinnspannen im steuerlichen Jahr sollte
   Zustimmungen und Produkteinführungen geschehen, wie wir uns projizieren.
   

Laiwang Zhang, Präsident und Vorsitzender von Sunwin internationales Neutraceuticals, kommentierte, „wir haben gebildet starke finanzielle Verpflichtungen in steuerlichen 2007, denen wir auftauchen in die Leistung 2008 der Firma glauben. Während diese Investitionen zu einer Abnahme in unseren gesamten Resultaten für 2007 beitrugen, sind wir überzeugt, daß sie erheblich unsere Aussichten für steuerliches Jahr 2008 und jenseits erhöhen. Wir fahren fort, neue Produkte zu entwickeln, um unsere Opfer im Marktplatz zu erweitern und sind überzeugt, daß steuerliche 2008 ein starkes Jahr sind, das auf den Entscheidungen basiert, die getroffen werden 2007.“

 
Back to Headlines | Previous Story  
 
StockConsultant
Enter Symbol
 


 
Dutton Associates Announces Investment Opinion: Sunwin International Neutraceuticals Speculative Buy Rating In Update Coverage By Dutton Associates



EL DORADO HILLS, Calif.--(BUSINESS WIRE)--

Dutton Associates updates its coverage of Sunwin International Neutraceuticals (OTCBB:SUWN) with a Speculative Buy rating and a price target of $.65. The 13-page report by Dutton senior analyst Stanley Ng is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.

Sunwin International Neutraceuticals recently announced its financial results for the fourth quarter and fiscal year 2007 ended April 30, 2007, which were rather disappointing and were below our downward revised forecasts in January 2007. The poor financial results were attributable to decline in demand for TCM and animal medicines, severe margins erosion due to increase in raw material costs and significant increase in operating expenses. As a result, price performance of the stock has been punished for the poor financial results. Despite the poor financial results in FY2007, we believe Sunwin is on its way to a strong recovery beginning in FY2008 for both revenue and net income. As farmers and breeders have begun slowly increasing their livestock population to normal levels, and assuming no further recurrence of avian flu or similar infections, sales of TCM and animal medicines will return to prior levels as government regulations have eased along with a decline in reports of avian flu. As for the Company's natural sweetener operation, recent reports of significant progress on penetrating the North American markets, shipments of OnlySweet (TM) to major grocery outlets in the US and reorders from the Company's largest customer are clear signs of increasing sales of its natural sweetener products. In addition, the commenced shipment of the 120-ton order for the much higher premium stevia from a Korean company should start making visible contributions to revenue and net income beginning in 2Q 2008.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 30 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. The Firm does not accept any equity compensation. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing on 05/08/2006. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Source: Sunwin International Neutraceuticals